Vertex Pharmaceuticals (VRTX) Cash & Current Investments (2009 - 2026)
Vertex Pharmaceuticals (VRTX) posted quarterly Cash & Current Investments of $7.2 billion for Q1 2026, up 16.86% year-over-year from $6.2 billion in Q1 2025, and up 9.66% quarter-over-quarter from $6.6 billion in Q4 2025.
Vertex Pharmaceuticals (VRTX) Cash & Current Investments (2009 - 2026) Analysis & Trends
Vertex Pharmaceuticals' Cash & Current Investments history runs 18 years deep, the most recent figure standing at $7.2 billion for Q1 2026.
- In Q1 2026, Cash & Current Investments rose 16.86% year-over-year to $7.2 billion; the TTM figure through Mar 2026 stood at $7.2 billion (up 16.86% YoY), while the FY2025 annual figure was $6.6 billion, up 8.05% from the prior year.
- Cash & Current Investments for Q1 2026 stood at $7.2 billion, up from $6.6 billion in the prior quarter.
- The five-year high for Cash & Current Investments was $11.9 billion in Q3 2023, with the low at $5.8 billion in Q2 2024.
- The 5-year median for Cash & Current Investments is $8.2 billion (2022), against an average of $8.5 billion.
- The sharpest annual moves came in 2022 and 2024: Cash & Current Investments soared 43.24% in 2022, then plunged 48.42% in 2024.
- Vertex Pharmaceuticals' Cash & Current Investments stood at $10.8 billion in 2022, then rose by 4.08% to $11.2 billion in 2023, then plunged by 45.48% to $6.1 billion in 2024, then rose by 8.05% to $6.6 billion in 2025, then advanced by 9.66% to $7.2 billion in 2026.
- Business Quant data shows VRTX's Cash & Current Investments at $7.2 billion in Q1 2026, $6.6 billion in Q4 2025, and $6.3 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 836.99 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.16 Bn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.85 Bn |
| Mar 31, 2026 | 7.25 Bn |
| Dec 31, 2025 | 6.61 Bn |
| Sep 30, 2025 | 6.29 Bn |
| Jun 30, 2025 | 6.38 Bn |
| Mar 31, 2025 | 6.20 Bn |
| Dec 31, 2024 | 6.12 Bn |
| Sep 30, 2024 | 6.52 Bn |
| Jun 30, 2024 | 5.80 Bn |
| Mar 31, 2024 | 10.17 Bn |
| Dec 31, 2023 | 11.22 Bn |
| Sep 30, 2023 | 11.93 Bn |
| Jun 30, 2023 | 11.24 Bn |
| Mar 31, 2023 | 10.41 Bn |
| Dec 31, 2022 | 10.78 Bn |
| Sep 30, 2022 | 9.77 Bn |
| Jun 30, 2022 | 9.25 Bn |
| Mar 31, 2022 | 8.24 Bn |
| Dec 31, 2021 | 7.52 Bn |
| Sep 30, 2021 | 6.96 Bn |